

Sen. John J. Cullerton

Filed: 4/3/2008

	09500SB2222sam004 LRB095 18675 RAS 48829 a
1	AMENDMENT TO SENATE BILL 2222
2	AMENDMENT NO Amend Senate Bill 2222, AS AMENDED,
3	by replacing everything after the enacting clause with the
4	following:
5	"Section 5. The Illinois Insurance Code is amended by
6	changing the heading of Article XXXI 1/2 and Sections 512-1,
7	512-2, 512-3, 512-4, 512-5, 512-6, 512-7, 512-8, 512-9, and
8	512-10 and by adding Sections 512-7.5, 512-7.10, 512-11,
9	512-12, and 512-13 as follows:
10	(215 ILCS 5/Art. XXXI.5 heading)
11	ARTICLE XXXI 1/2.
12	PHARMACEUTICAL BENEFITS MANAGEMENT THIRD PARTY PRESCRIPTION
13	PROGRAMS
14	(215 ILCS 5/512-1) (from Ch. 73, par. 1065.59-1)
15	Sec. 512-1. Short Title. This Article shall be known and

09500SB2222sam004 -2- LRB095 18675 RAS 48829 a

1 may be cited as the "Pharmaceutical Benefits Management 2 Programs Law Third Party Prescription Program Act". (Source: P.A. 82-1005.) 3 4 (215 ILCS 5/512-2) (from Ch. 73, par. 1065.59-2) 5 Sec. 512-2. Purpose. It is hereby determined and declared that the purpose of this Article is to regulate pharmaceutical 6 7 benefits management programs certain practices engaged in by 8 third-party prescription program administrators. 9 (Source: P.A. 82-1005.) (215 ILCS 5/512-3) (from Ch. 73, par. 1065.59-3) 10 11 Sec. 512-3. Definitions. For the purposes of this Article, unless the context otherwise requires, the terms defined in 12 13 this Article have the meanings ascribed to them herein: 14 "Covered entity" means any entity that has entered into an agreement, directly or indirectly, with a pharmaceutical 15 benefits manager to provide a pharmaceutical benefits 16 management program. "Covered entity" includes, but is not 17 18 limited to, a person or entity that has entered into a group contract for health care services with an insurer, Health 19 Maintenance Organization, Limited Health Services Organization 20 or Voluntary Health Services Plan under which the 21 pharmaceutical benefits manager is contractually obligated to 22 23 provide a pharmaceutical benefits management program. "Covered individual" means a member, participant, 24

enrollee, contract holder, policy holder, or beneficiary of a 1 2 covered entity who is provided health coverage by the covered entity. "Covered individual" includes, but is not limited to, a 3 4 dependent or other person who is provided health coverage 5 though a policy, contract, or plan for a covered individual. 6 "Director" means the Director of the Division of Insurance of the Department of Financial and Professional Regulation. 7 "Division" means the Division of Insurance of the 8 9 Department of Financial and Professional Regulation. 10 "Maximum allowable cost" or "MAC" means the maximum per 11 unit reimbursement as established and determined by the pharmaceutical benefits manager for a drug, medical product, or 12 13 device at the time a claim is processed. 14 "Pharmaceutical benefits management program" or "program" 15 means any system established by contract or otherwise of (i) 16 providing for the administration of or reimbursement for pharmaceutical services and prescription drug products offered 17 or operated in this State by a PBM for or on behalf of a covered 18 19 entity or (ii) procuring prescription drugs at a negotiated 20 for dispensation to covered individuals by a rate 21 pharmaceutical benefits manager operating in this State. "Pharmaceutical benefits manager " or " PBM" means any 22 23 person, partnership, or corporation that issues or causes to be 24 issued any payment or reimbursement to a provider for services 25 rendered pursuant to a pharmaceutical benefits management 26 program or an entity that procures prescription drugs at a

1	negotiated rate. "Pharmaceutical benefits manager " or " PBM"
2	does not include the Director of Healthcare and Family Services
3	or any agent authorized by the Director of Healthcare and
4	Family Services to reimburse or procure prescription drugs at a
5	negotiated rate pursuant to a program of which the Department
6	of Healthcare and Family Services is the third party.
7	"Pharmacy" has the meaning given to the term in the
8	Pharmacy Practice Act.
9	"Pharmacy network provider" means a pharmacist or pharmacy
10	that has a contractual relationship with a health benefit plan
11	or pharmacy benefit manager to provide pharmacist services.
12	"Pharmacy reimbursement rate" means the amount a PBM pays
13	to a pharmacy or pharmacy network provider for prescription
14	drugs and services provided by the pharmacy or pharmacy network
14 15	provider to the PBM.
15	provider to the PBM.
15 16	provider to the PBM. "Rebates" means any valuable consideration or inducement
15 16 17	provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of
15 16 17 18	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services.</pre>
15 16 17 18 19	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services. (a) "Third party prescription program" or "program" means</pre>
15 16 17 18 19 20	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services. (a) "Third party prescription program" or "program" means any system of providing for the reimbursement of pharmaceutical</pre>
15 16 17 18 19 20 21	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services. (a) "Third party prescription program" or "program" means any system of providing for the reimbursement of pharmaceutical services and prescription drug products offered or operated in</pre>
15 16 17 18 19 20 21 22	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services. (a) "Third party prescription program" or "program" means any system of providing for the reimbursement of pharmaceutical services and prescription drug products offered or operated in this State under a contractual arrangement or agreement between</pre>
15 16 17 18 19 20 21 22 23	<pre>provider to the PBM. "Rebates" means any valuable consideration or inducement to directly or indirectly affect or influence the dispensing of pharmaceutical drugs, supplies, or services. (a) "Third party prescription program" or "program" means any system of providing for the reimbursement of pharmaceutical services and prescription drug products offered or operated in this State under a contractual arrangement or agreement between a provider of such services and another party who is not the</pre>

1	pharmaceutical services and those services are paid for by an
2	agent of the employer or others.
3	(b) "Third party program administrator" or "administrator"
4	means any person, partnership or corporation who issues or
5	causes to be issued any payment or reimbursement to a provider
6	for services rendered pursuant to a third party prescription
7	program, but does not include the Director of Healthcare and
8	Family Services or any agent authorized by the Director to
9	reimburse a provider of services rendered pursuant to a program
10	of which the Department of Healtheare and Family Services is
11	the third party.
12	(Source: P.A. 95-331, eff. 8-21-07.)
13	(215 ILCS 5/512-4) (from Ch. 73, par. 1065.59-4)
14	Sec. 512-4. Licensure; application and fees Registration.
15	(a) No person, partnership, corporation, or other entity
16	may act as a PBM in this State without being licensed by the
17	Division.
18	(b) Each applicant for licensure must file with the
19	Director the following information and documents:
20	(1) the name of the company and the state or country
21	under the laws of which the company is organized or
22	authorized;
23	(2) the title of the Act under or by which the company
24	was incorporated or organized, the date of its
25	incorporation or organization, and, if a corporation, the

1	period of its duration;
2	(3) an organizational chart describing the
3	relationship between the PBM, its parent organization and
4	any affiliates, including the state or country of domicile
5	and the primary business of each entity;
6	(4) a list of the names, addresses, official positions,
7	and biographical affidavits of the persons responsible for
8	the conduct of the affairs of the PBM;
9	(5) sample copies of contracts utilized by the PBM
10	between the PBM and covered entities; if the terms and
11	conditions in such agreements include significant,
12	substantial, or material variations, the filing of one
13	complete sample agreement together with a description of
14	all variable terms and conditions may satisfy this
15	requirement; and
16	(6) such other information as the Director may
17	reasonably require.
18	(c) A licensee shall keep current the information required
19	to be disclosed in its application for licensure by reporting
20	all material changes or additions to the Director within 30
21	days after the end of the month of each change or addition. A
22	material change or addition includes any modification of the
23	information that has a significant effect on the operation of
24	the PBM.
25	(d) Beginning on January 1, 2009, each PBM doing business
26	in this State must pay to the Director an initial licensure fee

09500SB2222sam004 -7- LRB095 18675 RAS 48829 a

1 of \$1,000.00. Thereafter, annually on or before January 1 of each year, a PBM doing business in this State that seeks to 2 renew a PBM license must pay to the Director a renewal fee of 3 4 \$250. All fees collected under this Section shall be deposited 5 into the Insurance Producer Administration Fund. All third party prescription programs and administrators doing business 6 in the State shall register with the Director of Insurance. The 7 Director shall promulgate regulations establishing criteria 8 9 for registration in accordance with the terms of this Article. 10 The Director may by rule establish an annual registration fee for each third party administrator. 11

12 (Source: P.A. 82-1005.)

13 (215 ILCS 5/512-5) (from Ch. 73, par. 1065.59-5)

Sec. 512-5. <u>Disciplinary grounds; multiple accounts</u> Fiduciary and Bonding Requirements.

16 <u>(a) The Director may place on probation, suspend, revoke,</u> 17 <u>or refuse to issue or renew a pharmaceutical benefits</u> 18 <u>management program or PBM license or may levy a civil penalty</u> 19 <u>in accordance with this Section or take any combination of</u> 20 <u>actions for any one or more of the following causes:</u>

21 (1) Providing incorrect, misleading, incomplete, or
 22 materially untrue information in the license application.
 23 (2) Violating any provision of this Law or the
 24 insurance laws of this or another state or violating any
 25 rule, subpoena, or order of the Director of this or another

1	state's insurance commissioner.
2	(3) Obtaining or attempting to obtain a license through
3	misrepresentation or fraud.
4	(4) Improperly withholding, misappropriating, or
5	converting any moneys or properties received in the course
6	of doing business.
7	(5) Intentionally misrepresenting the terms of any
8	contract or agreement between a PBM and a covered entity.
9	(6) Having admitted to or been found to have committed
10	any unfair trade practice or fraud.
11	(7) Using fraudulent, coercive, or dishonest practices
12	or demonstrating incompetence, untrustworthiness, or
13	financial irresponsibility in the conduct of business in
14	this State or elsewhere.
15	(8) Having a professional license or registration or
16	its equivalent denied, suspended, or revoked in any other
17	state, province, district, or territory.
18	(9) Forging a name to an application.
19	(10) Failing to pay any tax or fee, as required by law.
20	(b) If the action by the Director is to deny renewal,
21	suspend, or revoke a license or to deny an application for a
22	licensure, the Director shall notify the applicant and advise,
23	in writing, the applicant of the reason for the suspension,
24	revocation, or denial. The applicant or licensee may make
25	written demand upon the Director within 30 days after the date
26	of mailing of notice for a hearing before the Director to

1	determine the reasonableness of the Director's action. The
2	hearing must be held within not fewer than 20 days nor more
3	than 30 days after the mailing of the notice of hearing and
4	shall be held pursuant to the Illinois Administrative Code.
5	(c) In addition to or instead of any applicable denial,
6	suspension, or revocation of a license, an applicant or
7	licensee may, after hearing, be subject to a civil penalty.
8	(d) The Director has the authority to enforce the
9	provisions of and impose any penalty or remedy authorized by
10	this Article against any person or PBM who is under
11	investigation for or charged with a violation of this Law or
12	Code even if the license has been surrendered or has lapsed by
13	operation of law.
14	(e) Upon the suspension, denial, or revocation of a
15	license, the licensee having possession or custody of the
16	license shall promptly deliver it to the Director in person or
17	by mail. The Director shall publish all suspensions, denials,
18	or revocations after the suspension, denial, or revocation
19	becomes final.
20	(f) A licensee whose license is revoked or applicant whose
21	application is denied pursuant to this Section is ineligible to
22	apply for any pharmaceutical benefits management program or PBM
23	license under this Law for 3 years after the revocation or
24	denial. A pharmaceutical benefits management program or PBM
25	whose license as a pharmaceutical benefits management program
26	or PBM has been revoked, suspended, or denied may not be

1 employed, contracted, or engaged in any related capacity during the time the revocation, suspension, or denial is in effect. 2 (g) A PBM must inform the Director in a manner acceptable 3 4 to the Director of a change of address within 30 days after the 5 change. A third party prescription program administrator shall (1) establish and maintain a fiduciary account, separate and 6 7 apart from any and all other accounts, for the receipt and disbursement of funds for reimbursement of providers of 8 9 services under the program, or (2) post, or cause to be posted, 10 a bond of indemnity in an amount equal to not less than 10% of the total estimated annual reimbursements under the program. 11

12 The establishment of such fiduciary accounts and bonds 13 shall be consistent with applicable State law. If a bond of 14 indemnity is posted, it shall be held by the Director of 15 Insurance for the benefit and indemnification of the providers 16 of services under the third party prescription program.

17 <u>(h) Any PBM</u> An administrator who operates more than one 18 <u>pharmaceutical benefits management</u> third party prescription 19 program may establish and maintain a separate fiduciary account 20 or bond of indemnity for each such program, or may operate and 21 maintain a consolidated fiduciary account or bond of indemnity 22 for all such programs.

The requirements of this <u>subsection (h)</u> Section do not apply to any <u>pharmaceutical benefits management</u> third party prescription program administered by or on behalf of any insurance company, Health <u>Maintenance Organization</u>, <u>Limited</u> 09500SB2222sam004 -11- LRB095 18675 RAS 48829 a

Health Service Organization, or Voluntary Health Services Plan
 Care Service Plan Corporation or Pharmaceutical Service Plan
 Corporation authorized to do business in the State of Illinois.
 (Source: P.A. 82-1005.)

5 (215 ILCS 5/512-6) (from Ch. 73, par. 1065.59-6)

Notice of any change in the terms 6 Sec. 512-6. Notice. 7 of а pharmaceutical benefits management third party 8 prescription program, including but not limited to drugs 9 covered, reimbursement rates, co-payments, and dosage 10 quantity, shall be given to each enrolled pharmacy at least 30 days prior to the time it becomes effective. 11

12 (Source: P.A. 82-1005.)

13 (215 ILCS 5/512-7) (from Ch. 73, par. 1065.59-7)

Sec. 512-7. <u>Required program and contractual</u> provisions.

16 (a) Any agreement or contract entered into in this State 17 between a PBM the administrator of a program and a pharmacy 18 under a pharmaceutical benefits management program shall include a statement of the method and amount of reimbursement 19 20 to the pharmacy for services rendered to covered persons 21 enrolled in the program, the frequency of payment by the PBM 22 program administrator to the pharmacy for those services, and a 23 method for the adjudication of complaints and the settlement of 24 disputes between the contracting parties.

09500SB2222sam004 -12- LRB095 18675 RAS 48829 a

1	(b) Every prescription benefit management program shall
2	(1) A program shall provide an annual period of at least 30
3	days during which any pharmacy licensed under the Pharmacy
4	Practice Act may elect to participate in the program under the
5	program terms for at least one year. <u>Beginning January 1, 2009,</u>
6	all agreements between a pharmaceutical benefits management
7	program and any other person shall comply with the requirements
8	of this Law. To the extent that any such agreement renewed or
9	extended after December 31, 2008, fails to comply with the
10	requirements of this Law, such requirements shall be deemed to
11	be incorporated into those agreements by operation of law as of
12	the date of the renewal of execution.
1 0	(2) If compliance with the neguinements of this

13 (2) If compliance with the requirements of this 14 subsection (b) would impair any provision of a contract 15 between a program and any other person, and if the contract 16 provision was in existence before January 1, 1990, then 17 immediately after the expiration of those contract 18 provisions the program shall comply with the requirements 19 of this subsection (b).

20

26

(3) This subsection (b) does not apply if:

21 (A) the program administrator is a licensed health 22 maintenance organization that owns or controls a 23 pharmacy and that enters into an agreement or contract 24 with that pharmacy in accordance with subsection (a); 25 or

(B) the program administrator is a licensed health

organization that is owned 1 or maintenance by another entity that also owns or 2 controls pharmacy, and the administrator enters 3 into 4 agreement or contract with that pharmacy in accordance 5 with subsection (a). (4) This subsection (b) shall be inoperative 6 after October 31, 1992. 7 8 (c) (Blank). The program administrator shall cause to be 9 issued an identification card to each person enrolled in the 10 program. The identification card shall include: (1)11 the name of the individual enrolled in the program; 12 and 13 (2) an expiration date if required under the 14 contractual arrangement or agreement between a provider 15 pharmaceutical services and prescription drug products and 16 the third party prescription program administrator. (Source: P.A. 95-689, eff. 10-29-07.) 17 (215 ILCS 5/512-7.5 new) 18 19 Sec. 512-7.5. Disclosures. (a) A PBM or pharmaceutical manufacturer shall provide to a 20 21 covered entity all appropriate financial and utilization information in aggregate relating to the cost of services to 22 23 that covered entity. A PBM or pharmaceutical manufacturer 24 providing information under this subsection (a) shall designate that information as confidential. Information 25

1 designated as confidential by a PBM and provided to a covered entity under this subsection (a) shall not be disclosed by the 2 3 covered entity to any person without the consent of the PBM or 4 pharmaceutical manufacturer, except that disclosure may be 5 made in a court filing or when authorized by law or ordered by a court of this State for good cause. Any unauthorized 6 7 disclosure by a PBM or covered entity of information that is 8 protected by the Illinois Trade Secrets Act shall result in a 9 civil penalty of \$10,000 per incident and, where disclosure is 10 found to be willful, punitive damages may apply.

11 (b) A PBM shall disclose to the covered entity all 12 appropriate financial terms and arrangements for remuneration 13 of any kind resulting from arrangements between the PBM and any 14 labeler, including without limitation formulary management and 15 drug-switch programs and specifically excluding any financial 16 terms and arrangements with prescription drug manufacturers, educational support, claims processing, and pharmacy network 17 fees that are charged from retail pharmacies and data sales 18 19 fees. Any and all information disclosed under this subsection 20 (b) may be designated as confidential. Information designated 21 as confidential by a PBM and provided to a covered entity under 22 this subsection (b) may not be disclosed by the covered entity 23 to any person without the consent of the PBM, except as may be 24 required in a court of law with proper jurisdiction or as 25 authorized by law.

26 (c) A PBM shall disclose to each covered entity and covered

1	individual, either electronically or in writing and in a manner
2	calculated to be understood by layperson, all of the following
3	information:
4	(1) The amount of copayment, coinsurance, and
5	deductible associated with each and every tier of covered
6	prescription drugs.
7	(2) A notice to the covered individual advising the
8	covered individual to contact the PBM before filling or
9	obtaining a refill for a particular prescription drug the
10	covered individual is currently using to determine whether
11	there has been any change in (i) the requirements for
12	obtaining coverage for the drug or (ii) the amount that the
13	covered individual is required to pay out-of-pocket for the
14	drug.
15	(3) A notice to the covered individual advising the
16	covered individual to consider contacting his or her
17	prescribing provider to determine whether there is an
18	acceptable generic or other alternative prescription drug
19	that can be used to treat the covered individual's disease
20	or medical condition that is available at a lower
21	<u>out-of-pocket level.</u>
22	(d) Nothing in this Section shall prohibit a pharmacy
23	network provider from advising a covered individual of (i)
24	alternative generic prescription drugs that might be available
25	to the covered individual at a lower out-of-pocket level and
26	(ii) that the covered individual may contact his or her

prescribing provider to determine whether there is an acceptable alternative prescription drug that can be used to treat the covered individual's disease or medical condition that is available at a lower out-of-pocket level.

5 (215 ILCS 5/512-7.10 new)

Sec. 512-7.10. Recoupment. A PBM shall provide the pharmacy 6 or pharmacy network provider a remittance advice which must 7 include an explanation of a recoupment or offset taken by a 8 9 PBM, if any. The recoupment explanation shall, at a minimum, 10 include the name of the patient, the date of dispensing, the prescription drug or drugs dispensed, the recoupment amount, 11 12 and the reason for the recoupment or offset. In addition, a PBM 13 shall provide with the remittance advice a telephone number or 14 mailing address to initiate an appeal of the recoupment or 15 offset.

16 (215 ILCS 5/512-8) (from Ch. 73, par. 1065.59-8)

17 Sec. 512-8. Cancellation procedures.

(a) The <u>pharmacy benefits manager</u> administrator of a
program shall notify all pharmacies enrolled in the program of
any cancellation of the coverage of benefits of any group
enrolled in the program at least 30 days prior to the effective
date of such cancellation. However, if the <u>PBM</u> administrator of
a program is not notified at least 45 days prior to the
effective date of such cancellation, the <u>PBM</u> administrator

1 shall notify all pharmacies enrolled in the program of the 2 cancellation as soon as practicable after having received 3 notice.

4 (b) When a program is terminated, all persons enrolled
5 therein shall be so notified by the PBM, and the employer shall
6 make every reasonable effort to gain possession of any plan
7 identification cards in such persons' possession.

who intentionally uses 8 (C) Any person а program 9 identification card to obtain services from a pharmacy after 10 having received notice of the cancellation of his benefits 11 shall be quilty of a Class C misdemeanor. Persons shall be liable to the PBM program administrator for all monies paid by 12 13 the PBM program administrator for any services received pursuant to any improper use of the identification card. 14 15 (Source: P.A. 82-1005.)

16 (215 ILCS 5/512-9) (from Ch. 73, par. 1065.59-9)

17 Sec. 512-9. Denial of Payment.

18 (a) No PBM administrator shall deny payment to any pharmacy 19 for covered pharmaceutical services or prescription drug products rendered as a result of the misuse, fraudulent or 20 21 illegal use of an identification card unless such 22 identification card had expired, been noticeably altered, or 23 the pharmacy was notified of the cancellation of such card. In 24 lieu of notifying pharmacies which have a common ownership, the 25 PBM administrator may notify a party designated by the pharmacy

to receive such notice, in which case, notification shall not become effective until 5 calendar days after the designee receives notification.

4 (b) No PBM program administrator may withhold any payment 5 to any pharmacy for covered pharmaceutical services or prescription drug products beyond the time period specified in 6 the payment schedule provisions of the agreement, except for 7 8 individual claims for payment which have been returned to the 9 pharmacy as incomplete or illegible. Such returned claims shall 10 be paid if resubmitted by the pharmacy to the PBM program 11 administrator with the appropriate corrections made.

12 (c) No PBM may deny a claim for payment for filling a 13 prescription from a network pharmacy provider that exceeds the 14 MAC, unless the PBM advises the network pharmacy provider how 15 to obtain the particular drug at the MAC rate.

16 (Source: P.A. 82-1005.)

17 (215 ILCS 5/512-10) (from Ch. 73, par. 1065.59-10)

18 Sec. 512-10. Failure to obtain licensure Register. Any 19 pharmaceutical benefits management third party prescription 20 program or PBM that administrator which operates without a 21 license certificate of registration or fails to register with 22 the Director and pay the fee prescribed by this Article shall 23 be construed to be an unauthorized insurer as defined in 24 Article VII of this Code and shall be subject to all penalties 25 contained therein.

1	The provisions of the Article shall apply to all new
2	programs established on or after January 1, 1983. Existing
3	programs shall comply with the provisions of this Article on
4	the anniversary date of the programs that occurs on or after
5	January 1, 1983.
6	(Source: P.A. 82-1005.)
7	(215 ILCS 5/512-11 new)
8	Sec. 512-11. Examination of business and affairs.
9	(a) The Director may, when and as often as the Director
10	deems it reasonably necessary to protect the interests of the
11	public, examine the business and affairs of any licensed PBM.
12	(b) Licensees shall maintain for a period of 5 years copies
13	of all documents, books, records, accounts, papers, and any or
14	all computer or other recordings relating to the licensee's
15	business and affairs of operating a pharmaceutical benefit
16	management program.
17	(c) Every licensee or person from whom information is
18	sought, including all officers, directors, employees and
19	agents of any licensee or person from whom information is
20	sought, shall provide to the examiners timely, convenient, and
21	free access at all reasonable hours at the licensee's or
22	person's offices to all books, records, accounts, papers,
23	documents, assets, and computer or other recordings relating to
24	the property, assets, business, and affairs of the licensee
25	being examined. The officers, directors, employees, and agents

1	of the licensee or person shall facilitate the examination and
2	aid in the examination so far as it is in their power to do so.
3	The refusal of a licensee, through its officers, directors,
4	employees, or agents, to submit to examination or to comply
5	with any reasonable written request of the Director shall be
6	grounds for suspension, revocation, or denial of issuance or
7	renewal of any license or authority held by the licensee
8	pursuant to this Law.
9	(d) The Director or his or her designee shall have the
10	power to issue subpoenas, administer oaths, and examine under
11	oath any person as to any matter pertinent to the examination.
12	Upon the failure or refusal of a person to obey a subpoena, the
13	Director may petition a court of competent jurisdiction, and
14	upon proper showing, the court may enter an order compelling
15	the witness to appear and testify or produce documentary
16	evidence.
17	(e) When making an examination under this Law, the Director
18	may retain attorneys, appraisers, independent actuaries,
19	independent certified public accountants, or other
20	professionals and specialists as examiners. The costs of
21	retaining the examiners, including their work, travel, and
22	living expenses shall be borne by the licensee that is the
23	subject of the examination.

24 (215 ILCS 5/512-12 new)

25 Sec. 512-12. Fines and penalties. In addition to or instead 09500SB2222sam004 -21- LRB095 18675 RAS 48829 a

1	of any applicable denial, suspension, or revocation of a
2	license issued under this Law, a licensee may, after a hearing,
3	be subject to a civil penalty of up to \$500,000 for each cause
4	of denial, suspension, or revocation.
5	Any licensee or other person who willfully or repeatedly
6	fails to observe or who otherwise violates any of the
7	provisions of this Law or this Code or any rule adopted or
8	final order entered thereunder shall, by civil penalty, forfeit
9	to the Division a sum not to exceed \$5,000. Each day during
10	which a violation occurs constitutes a separate offense.
11	(215 ILCS 5/512-13 new)
12	Sec. 512-13. Rulemaking. The Director shall have the
13	authority to adopt any rules necessary for the implementation

14 <u>and administration of this Article.</u>".